Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oral Medicine: a retrospective analysis of patient profiles, diagnoses, and referral patterns in Mexico City.

Medicina oral, patologia oral y cirugia bucal·2025
Same author

Myofibromas of the jawbones in pediatric patients. A clinicopathological study.

Medicina oral, patologia oral y cirugia bucal·2025
Same author

Synchronous cemento-ossifying fibromas: a systematic review.

Medicina oral, patologia oral y cirugia bucal·2024
Same author

Histomorphological evaluation, cell proliferation and endothelial immunostaining in oral and maxillofacial myofibroblastic lesions.

Medicina oral, patologia oral y cirugia bucal·2022
Same author

Capsaicin intake and oral carcinogenesis: A systematic review.

Medicina oral, patologia oral y cirugia bucal·2021
Same author

Oral vesiculobullous lesions as an early sign of COVID-19: immunohistochemical detection of SARS-CoV-2 spike protein.

The British journal of dermatology·2020

Related Experiment Video

Updated: Jul 15, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Ameloblastomas: a regional Latin-American multicentric study.

C Ledesma-Montes1, A Mosqueda-Taylor, R Carlos-Bregni

  • 1Oral Pathology Laboratory, Facultad de Odontología, Universidad Nacional Autónoma de México, México, DF México. cledezma@servidor.unam.mx

Oral Diseases
|April 24, 2007
PubMed
Summary

Unicystic ameloblastoma (UA) is often misdiagnosed as solid ameloblastoma (SA), but distinct clinical and microscopic features allow accurate differentiation for improved surgical and prognostic outcomes. UA was more frequent and less recurrent than SA.

More Related Videos

Translationally-Relevant Tumor Resection Model for Murine Preclinical Models of Oral Squamous Cell Carcinoma
07:59

Translationally-Relevant Tumor Resection Model for Murine Preclinical Models of Oral Squamous Cell Carcinoma

Published on: April 3, 2026

Related Experiment Videos

Last Updated: Jul 15, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Translationally-Relevant Tumor Resection Model for Murine Preclinical Models of Oral Squamous Cell Carcinoma
07:59

Translationally-Relevant Tumor Resection Model for Murine Preclinical Models of Oral Squamous Cell Carcinoma

Published on: April 3, 2026

Area of Science:

  • Oral Pathology
  • Odontogenic Tumours
  • WHO Classification

Background:

  • Ameloblastomas are the most common odontogenic tumours.
  • Accurate classification is crucial for patient management.
  • The 2005 WHO Classification provides updated diagnostic criteria.

Purpose of the Study:

  • To classify 163 ameloblastoma cases using the WHO Classification (2005).
  • To analyze the clinical and microscopic features of ameloblastomas.
  • To differentiate between solid ameloblastoma (SA) and unicystic ameloblastoma (UA).

Main Methods:

  • Retrospective analysis of 163 ameloblastoma cases.
  • Data collected from nine Latin-American institutions.
  • Evaluation of clinico-pathological features.

Main Results:

  • Ameloblastomas constitute 22.7% of odontogenic tumours.
  • Unicystic ameloblastoma (UA) was twice as frequent as solid ameloblastoma (SA).
  • Mean age for SA was 41.4 years, for UA was 26.3 years; mandible was the primary site for both; recurrence rates were 21.7% for SA and 12.6% for UA.

Conclusions:

  • UA is frequently misdiagnosed as SA.
  • Distinct clinical and microscopic features aid accurate differentiation of UA and SA.
  • Recognizing these differences is vital for surgical and prognostic purposes.